NCT04905147 is a NA clinical trial of Mosapride in Colorectal Cancer, sponsored by Mahidol University.

Who is sponsoring NCT04905147?

NCT04905147 is sponsored by Mahidol University.

What drugs are being tested in NCT04905147?

Interventions in NCT04905147: Mosapride, Placebo.

What condition does NCT04905147 study?

NCT04905147 studies Colorectal Cancer, Bowel Ileus.

Is NCT04905147 still recruiting?

NCT04905147 is currently status unknown. Last updated 2 September 2021.

Last reviewed 2021-09-02 · How we verify

NCT04905147

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery

Status unknown NA Last updated 2 September 2021

What this trial tests

NA trial testing Mosapride in Colorectal Cancer in 44 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
31 July 2023

30 November 2023

Quick facts

Lead sponsor	Mahidol University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	44
Start date	1 July 2021
Primary completion	31 July 2023
Estimated completion	30 November 2023
Sites	1 location across Thailand

Drugs / interventions tested

Mosapride (MOSAPRIDE) — full drug profile →
Placebo

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Bowel Ileus — all drugs for Bowel Ileus →

Sponsor

Mahidol University

Who can join

Adults 15 to 70, any sex, with Colorectal Cancer or Bowel Ileus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postoperative ileus (POI) is one of the most common causes of prolonged hospital stays after abdominal surgery. The pathophysiology of POI is multifactorial and complex.It is known to be associated with sympathetic neural reflexes,local and systemic inflammatory mediators,and changes invarious neural and hormonal transmitters.Sympathetic (adrenergic) hyperactivity results in reduction of propulsive motility,and an increase in sphinctertone.Parasympathetic (cholinergic) hypoactivity results in adecrease in gastrointestinalmotility. Various agents called prokinetic drugs,including erythromycin, metoclopramide, cholinergic agents have been assessed in an effort to improved gastrointestinal motility. Mosapridecitrate is another prokinetic drug that selectively activates 5-HT4 receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects. We therefore investigate the effect of mosapride on postoperative gastrointestinal motility after open and laparoscopic colectomy in a prospective randomized, controlled study in patients under going colectomy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The efficacy of mosapride on recovery of intestinal motility after elective colorectal cancer surgery: a randomized controlled trial.
Thampongsa T, Saengsawang B, Supsamutchai C, Wilasrusmee C, et al · · 2025 · PMID 40598989 · DOI 10.3393/ac.2024.00892.0127
UEG Week 2023 Moderated Posters
· 2023

Verify or expand the search:

Other trials of Mosapride

Trials testing the same drug.

NCT03477266 — Mouth Dissolving Mosapride Tables Enhance Post Cesarean Gut Recovery · Phase 3 · completed

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04905147 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 2 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04905147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing